AML with NPM1 mutation is a clinically heterogeneous group likely due to the prevalence of concurrent mutations: 54% DNMT3A, 39% FLT3ITD, 19% NRAS, 16% TET2, and 15% PTPN11. This evidence concerns the gene TET2 and acute myeloid leukemia.